FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer Targeted Oncology
Finance, IT & News
FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI in mAPMN/S Prostate Cancer Targeted Oncology
FDA clears autoinjector drug for home treatment of heart failure edema Cardiovascular Business
FDA Approves Pluvicto Plus Hormone Therapy for Certain Patients With Metastatic Prostate Cancer Cure Today
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC Urology Times
Agibank Wins Fitch Upgrade to AA(bra), Cementing Hybrid Model After INSS Fraud Investigation Tech Times